Clinical trials: Neoadjuvant Therapy, open to volunteers
Lung Neoplasm Malignant
Preoperative Sintilimab Combined With Bevacizumab and Chemotherapy for Resectable Non-Small Cell Lung Cancer
Neoadjuvant chemotherapy followed by surgery has been recommended as the standard treatment for locally advanced and resectable non-small cell lung cancer (NSCLC). However, its efficacy remains to be improved.
- Trial name
- NCT04973293
- Testing
- sintilimab, bevacizumab
- Where
- China
- Volunteers
- 20 people
- Sponsor
- Ruijin Hospital
Endometrioid Endometrial Cancer
Clinical Efficacy Study of PD-1 Inhibitor Combined With Neoadjuvant Chemotherapy in Advanced Endometrial Cancer
Exploring the therapeutic effect of neoadjuvant chemotherapy combined with PD-1 inhibitor camrelizumab on advanced stage III-IV endometrial cancer
- Trial name
- NCT06561308
- Testing
- Camrelizumab, Carboplatin, Paclitaxel
- Where
- China
- Volunteers
- 39 people
- Sponsor
- Women's Hospital School Of Medicine Zhejiang University
Esophageal Squamous Cell Carcinoma
Adebrelimab With Famitinib and Chemotherapy as Neoadjuvant Therapy for ESCC
This is a prospective, single-arm, exploratory clinical study enrolling patients with resectable, locally advanced thoracic esophageal squamous cell carcinoma (ESCC) confirmed by histology or cytology.
- Trial name
- NCT07796113
- Testing
- Adebrelimab + Famitinib + Chemotherapy
- Where
- China
- Volunteers
- 24 people
- Sponsor
- First Affiliated Hospital Xi'an Jiaotong University
TNBC - Triple-Negative Breast Cancer
Real-world Treatment Outcomes and Safety of Neoadjuvant Pembrolizumab-containing Therapy in Patients With Triple-negative Breast Cancer: Korean Nationwide Multicenter Study (Pembro-Real World)
The purpose of this study is to evaluate the treatment outcomes and safety of neoadjuvant therapy including pembrolizumab in real-world practice for patients with triple-negative breast cancer (TNBC) in a multi-center study in…
- Trial name
- NCT07828652
- Testing
- Medical record use research
- Volunteers
- 2,000 people
- Sponsor
- Yeon Hee Park
Triple Negative Breast Cancer
Neoadjuvant Pembrolizumab, Carboplatin and Paclitaxel in Triple-negative Breast Cancer
This is a phase II, single-centered, open-label, single-armed study in patients with early triple-negative breast cancer that will evaluate the pathological complete response (pCR) rate of a non-anthracycline-based…
- Trial name
- NCT06407310
- Testing
- Pembrolizumab, Carboplatin, Paclitaxel
- Volunteers
- 25 people
- Sponsor
- Tel Aviv Medical Center
Triple Negative Breast Neoplasms
Utidelone (UTD1) Plus Capecitabine in Non-pCR TNBC After Neoadjuvant Therapy
This trial is a multicenter, single-arm clinical trial to evaluate the efficacy and safety of UTD1 in combination with capecitabine for the adjuvant treatment of TNBC patients who did not achieve pathologic complete remission…
- Trial name
- NCT06385990
- Testing
- UTD1
- Where
- China
- Volunteers
- 53 people
- Sponsor
- Hunan Cancer Hospital
Non-surgical Management;dMMR/MSI-H Gastric Cancer;Neoadjuvant Immunotherapy
Non-surgical Management After NIT for dMMR/MSI-H GC
Gastric cancer is one of the most common cancers worldwide and has a poor prognosis Immunotherapy significantly improves the prognosis of gastric cancer.
- Trial name
- NCT07646574
- Where
- China
- Volunteers
- 12 people
- Sponsor
- Yong Zhou
Colorectal Carcinoma (CRC), Complications
Perioperative Outcomes After Neoadjuvant Therapy in Colorectal Cancer
This prospective study investigates the effects of neoadjuvant therapy on endothelial function, microvascular tissue density, and tissue fibrosis in patients with colorectal cancer and their association with perioperative…
- Conditions
- Colorectal Carcinoma (CRC), Complications, Neoadjuvant Therapy, Endothelial Dysfunction
- Trial name
- Neocolon (NCT07422974)
- Testing
- Skin and subcutaneous tissue sampling for histopathological analysis, Blood sampling for laboratory analyses before and after surgery
- Where
- Croatia
- Volunteers
- 68 people
- Sponsor
- Osijek University Hospital
Recurrent Head and Neck Squamous Cell Carcinoma
Anti-PD-1 Therapy in Recurrent and Metastatic Head and Neck Squamous Cell Carcinoma
The goal of this clinical trial is to determine whether a perioperative PD-1 antibody-based treatment strategy, consisting of neoadjuvant PD-1 antibody plus chemotherapy followed by adjuvant PD-1 antibody after surgery, improves…
- Trial name
- neo-Recur (NCT07751289)
- Testing
- Neoadjuvant PD-1 antibody plus chemotherapy, surgery, Adjuvant PD-1 antibody
- Volunteers
- 217 people
- Sponsor
- Yanjie Zhang, MD
Acute Myeloid Leukemia
IDH Targeted/Non- Targeted vs Non-targeted/IDH-targeted Approaches in the Treatment of Newly Diagnosed IDH Mutated AML Patients Not Candidates for Intensive Induction Therapy (I- DATA Study)
This phase II study compares the order of treatment with ivosidenib or enasidenib and azacitidine plus venetoclax in treating older patients with acute myeloid leukemia with genetic changes in the IDH1 or IDH2 genes (IDH…
- Trial name
- NCT05401097
- Testing
- Azacitidine, Biopsy, Enasidenib
- Where
- 4 sites in United States
- Volunteers
- 125 people
- Sponsor
- Alice Mims
Head and Neck Cancer, Neoadjuvant Therapy
Application of MRI Radiomics Features in Neoadjuvant Therapy of Head and Neck Squamous Cell Carcinoma
Head and neck squamous cell carcinoma is the sixth most common malignant tumor in the world. Neoadjuvant therapy, including neoadjuvant chemotherapy and immunotherapy, is recommended for patients with locally advanced head and…
- Conditions
- Head and Neck Cancer, Neoadjuvant Therapy, Immunotherapy, Chemotherapy
- Trial name
- NCT06755567
- Testing
- MRI-based radiomics-clinical model
- Where
- China
- Volunteers
- 750 people
- Sponsor
- Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
Head and Neck Squamous Cell Carcinoma
Neoadjuvant Adebrelimab Plus Dalpiciclib in Head and Neck Squamous Cell Carcinoma
This study is a single arm phase II trial including 30 patients with III-IVB (according to the 8th edition of UICC/AJCC staging) locally advanced head and neck squamous cell carcinoma (HNSCC) eligible for resection, who receive…
- Trial name
- NCT06199271
- Testing
- Adebrelimab and dalpiciclib
- Volunteers
- 30 people, healthy volunteers welcome
- Sponsor
- Zhongzheng Xiang
Breast Cancer
Neoadjuvant SHR-A1811 Combined With Pertuzumab in HER2-Positive Breast Cancer: An Exploratory Clinical Study.
This is a multicenter, two-arm, exploratory clinical study designed to evaluate the efficacy and safety of a response-guided neoadjuvant treatment strategy in patients with HER2-positive early or locally advanced breast cancer.
- Trial name
- NCT07528898
- Testing
- SHR-A1811, Pertuzumab, trastuzumab
- Where
- China
- Volunteers
- 100 people
- Sponsor
- Hebei Medical University Fourth Hospital
Rectal Cancer
Total Neoadjuvant mFOLFOX6 Plus Suvemcitug and Enlonstobart With Selective Omission of Pelvic Radiotherapy for High-Risk Mid-Rectal Locally Advanced Rectal Cancer
This is a prospective, multicenter, open-label, single-arm Phase II study designed to evaluate the efficacy and safety of total neoadjuvant mFOLFOX6 combined with suvemcitug and enlonstobart in patients with MRI（Magnetic…
- Trial name
- SPARE (NCT07810114)
- Testing
- mFOLFOX6, Suvemcitug, Enlonstobart
- Where
- China
- Volunteers
- 52 people
- Sponsor
- Fudan University
Rectal Cancer Patients, Total Neoadjuvant Therapy
Nodal Downstaging Versus Primary Tumor Regression as Predictors of Survival After Total Neoadjuvant Therapy for Rectal Cancer: A Retrospective Study
To evaluate the prognostic impact of post-TNT pathological nodal status (ypN) on LRFS, DMFS, and OS, and compare it with that of primary tumor response
- Trial name
- NCT07557316
- Where
- Egypt
- Volunteers
- 100 people
- Sponsor
- Sohag University
Rectal Cancer, Neoadjuvant Therapy
A Prospective Study of Expression Profiling-based Assessment of the Efficacy of Neoadjuvant Therapy for Rectal Cancer
This is a prospective study of expression profiling-based assessment of the efficacy of neoadjuvant therapy for rectal cancer.
- Trial name
- NCT06746298
- Volunteers
- 118 people
- Sponsor
- Shanghai Minimally Invasive Surgery Center
Localized Pancreatic Ductal Adenocarcinoma, Stage 0 Pancreatic Cancer AJCC v8
A Brief Psychological Intervention to Improve Emotional Well-Being During Neoadjuvant Therapy for Pancreatic Cancer
This clinical trial tests how well a psychosocial oncology intervention during neoadjuvant therapy works for patients with pancreatic cancer that has not spread to other parts of the body (localized).
- Conditions
- Localized Pancreatic Ductal Adenocarcinoma, Stage 0 Pancreatic Cancer AJCC v8, Stage I Pancreatic Cancer AJCC v8, Stage IIA Pancreatic Cancer AJCC v8
- Trial name
- NCT07124611
- Testing
- Interview, Nutritional Therapy, Physical Therapy
- Where
- United States
- Volunteers
- 60 people
- Sponsor
- Ohio State University Comprehensive Cancer Center
Extrahepatic Cholangiocarcinoma, Perihilar Cholangiocarcinoma
Neoadjuvant Gemcitabine and Cisplatin in Combination With Perioperative Pembrolizumab Versus Upfront Surgery for Patients With Primary Resectable and Borderline Resectable Perihilar and Distal Cholangiocarcinoma
Extrahepatic cholangiocarcinoma (eCCA) is a rare and aggressive cancer with poor prognosis. ECCA can be further subcategorised in perihilar and distal cholangiocarcinoma (pCCA and dCCA).
- Conditions
- Extrahepatic Cholangiocarcinoma, Perihilar Cholangiocarcinoma, Distal Cholangiocarcinoma, Resectable
- Trial name
- NEODISCO (NCT06923475)
- Testing
- Pembrolizumab, Gemcitabine, Cisplatin
- Where
- Netherlands
- Volunteers
- 150 people
- Sponsor
- Amsterdam UMC, location VUmc
ESCC
Adebrelimab Plus Full-course Neoadjuvant Therapy for Resectable Locally Advanced ESCC (Phase 2)
This is a prospective, single-center, randomized phase 2 study of adebrelimab plus full-course neoadjuvant therapy in resectable locally advanced esophageal squamous cell carcinoma.
- Trial name
- NAT-ESCC-01 (NCT07584031)
- Testing
- Combination therapy with chemotherapy and immunotherapy, Surgery
- Volunteers
- 200 people
- Sponsor
- Tianjin Medical University Cancer Institute and Hospital
Upper Tract Urothelial Carcinoma
NECTAR Study: Neoadjuvant Toripalimab + 9MW2821 for Local UTUC
The NECTAR study is a multicenter, open-label, randomized phase II clinical trial designed to evaluate a neoadjuvant treatment strategy in patients with localized upper tract urothelial carcinoma (UTUC).
- Trial name
- NECTAR (NCT07412171)
- Testing
- Toripalimab, 9MW2821, Radical Nephroureterectomy with or without Lymph Node Dissection
- Where
- China
- Volunteers
- 40 people
- Sponsor
- Peking University Third Hospital
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.